AXSOME THERAPEUTICS INC(NASDAQ:AXSM) stock News

AXSM Latest News, Press Relases and Analysis

All

Press Releases

13 days ago - By: Chartmill

Axsome Therapeutics Inc (NASDAQ:AXSM) Reports Q2 2025 Revenue Beat and Narrower EPS Loss, Shares Surge 6% in Pre-Market Trading

12 days ago - By: Benzinga

Axsome Therapeutics Analysts Increase Their Forecasts After Q2 Earnings

12 days ago - By: Zacks Investment Research - Mentions: JAZZ CRMD IMCR

AXSM Q2 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y

13 days ago - By: Benzinga

Where Axsome Therapeutics Stands With Analysts

13 days ago - By: The Motley Fool

Axsome (AXSM) Q2 Revenue Soars 72%

13 days ago - By: Axsome Therapeutics, Inc.

Axsome Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

13 days ago - By: Axsome Therapeutics, Inc.

Axsome Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

19 days ago - By: Zacks Investment Research - Mentions: AMGN

Amgen (AMGN) Reports Next Week: Wall Street Expects Earnings Growth

24 days ago - By: The Motley Fool - Mentions: SHOP JAZZ

2 Top Stocks I Wouldn't Hesitate to Invest $1,000 in Right Now

24 days ago - By: Yahoo Finance - Mentions: SHOP

2 Top Stocks I Wouldn't Hesitate to Invest $1,000 in Right Now

a month ago - By: Axsome Therapeutics, Inc.

Axsome Therapeutics Hosts Frontiers in Brain Health R&D Day Reviewing Industry-Leading Late-Stage CNS Pipeline

a month ago - By: Axsome Therapeutics, Inc.

Axsome Therapeutics Hosts Frontiers in Brain Health R&D Day Reviewing Industry-Leading Late-Stage CNS Pipeline

a month ago - By: Axsome Therapeutics, Inc.

Axsome Therapeutics to Ring the NASDAQ Stock Market Opening Bell Today

a month ago - By: Axsome Therapeutics, Inc.

Axsome Therapeutics to Ring the NASDAQ Stock Market Opening Bell Today

a month ago - By: Axsome Therapeutics, Inc.

Axsome Therapeutics to Report Second Quarter 2025 Financial Results on August 4

a month ago - By: Axsome Therapeutics, Inc.

Axsome Therapeutics to Report Second Quarter 2025 Financial Results on August 4

a month ago - By: Axsome Therapeutics, Inc.

Axsome Therapeutics to Showcase Its Innovative CNS Pipeline at Upcoming Frontiers in Brain Health R&D Day in New York City on July 21

a month ago - By: Axsome Therapeutics, Inc.

Axsome Therapeutics to Showcase Its Innovative CNS Pipeline at Upcoming Frontiers in Brain Health R&D Day in New York City on July 21

a month ago - By: Yahoo Finance - Mentions: MS

Morgan Stanley Assumes Coverage of Axsome Therapeutics (AXSM) with an Overweight Rating

2 months ago - By: Axsome Therapeutics, Inc.

Axsome Therapeutics Champions Brain Health During Alzheimer's & Brain Awareness Month

2 months ago - By: Axsome Therapeutics, Inc.

Axsome Therapeutics Champions Brain Health During Alzheimer's & Brain Awareness Month

2 months ago - By: Axsome Therapeutics, Inc.

Axsome Therapeutics to Present Data Spanning the SYMBRAVO® (meloxicam and rizatriptan) Clinical Program at the 67th Annual Scientific Meeting of the American Headache Society (AHS)

2 months ago - By: Axsome Therapeutics, Inc.

Axsome Therapeutics to Present Data Spanning the SYMBRAVO® (meloxicam and rizatriptan) Clinical Program at the 67th Annual Scientific Meeting of the American Headache Society (AHS)

2 months ago - By: Axsome Therapeutics, Inc.

Axsome Therapeutics Proudly Supports Migraine and Headache Awareness Month Alongside the Association of Migraine Disorders

2 months ago - By: Yahoo Finance - Mentions: RJF RNA NET CNXC ...

Avidity Biosciences, Inc. (RNA) Initiated with a Strong Buy at Raymond James

2 months ago - By: Yahoo Finance - Mentions: JPM REGN INTC RNA ...

JPMorgan Calls the Selloff Excessive, Trims Regeneron Pharmaceuticals, Inc. (REGN) Price Target

2 months ago - By: Yahoo Finance - Mentions: JAZZ CRWD NVDA INTC ...

Jazz Pharmaceuticals Releases Unexpected Phase 4 Results Highlighting Xywav®

2 months ago - By: Yahoo Finance - Mentions: MS VZ INSM EH ...

Axsome’s AXS-14 Gets Regulatory Setback with RTF, says Morgan Stanley

2 months ago - By: Yahoo Finance - Mentions: INSM WFC UTHR EH ...

Analyst Kelly Shi from Jefferies Maintained a Buy Rating on Insmed Incorporated (INSM)

2 months ago - By: Axsome Therapeutics, Inc.

Axsome Therapeutics Showcases Innovation in Sleep Medicine with Multiple Presentations for AXS-12 and Solriamfetol at SLEEP 2025

2 months ago - By: Axsome Therapeutics, Inc.

Axsome Therapeutics Showcases Innovation in Sleep Medicine with Multiple Presentations for AXS-12 and Solriamfetol at SLEEP 2025

2 months ago - By: Axsome Therapeutics, Inc.

AXSOME THERAPEUTICS INC (AXSM) Stock News

AXSM Latest News, Press Relases and Analysis

Axsome Therapeutics Inc (NASDAQ:AXSM) Reports Q2 2025 Revenue Beat and Narrower EPS Loss, Shares Surge 6% in Pre-Market Trading

Axsome Therapeutics Analysts Increase Their Forecasts After Q2 Earnings

AXSM Q2 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y

Where Axsome Therapeutics Stands With Analysts

Axsome (AXSM) Q2 Revenue Soars 72%

Axsome Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Axsome Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Amgen (AMGN) Reports Next Week: Wall Street Expects Earnings Growth

2 Top Stocks I Wouldn't Hesitate to Invest $1,000 in Right Now

2 Top Stocks I Wouldn't Hesitate to Invest $1,000 in Right Now

Axsome Therapeutics Hosts Frontiers in Brain Health R&D Day Reviewing Industry-Leading Late-Stage CNS Pipeline

Axsome Therapeutics Hosts Frontiers in Brain Health R&D Day Reviewing Industry-Leading Late-Stage CNS Pipeline

Axsome Therapeutics to Ring the NASDAQ Stock Market Opening Bell Today

Axsome Therapeutics to Ring the NASDAQ Stock Market Opening Bell Today

Axsome Therapeutics to Report Second Quarter 2025 Financial Results on August 4

Axsome Therapeutics to Report Second Quarter 2025 Financial Results on August 4

Axsome Therapeutics to Showcase Its Innovative CNS Pipeline at Upcoming Frontiers in Brain Health R&D Day in New York City on July 21

Axsome Therapeutics to Showcase Its Innovative CNS Pipeline at Upcoming Frontiers in Brain Health R&D Day in New York City on July 21

Morgan Stanley Assumes Coverage of Axsome Therapeutics (AXSM) with an Overweight Rating

Axsome Therapeutics Champions Brain Health During Alzheimer's & Brain Awareness Month

Axsome Therapeutics Champions Brain Health During Alzheimer's & Brain Awareness Month

Axsome Therapeutics to Present Data Spanning the SYMBRAVO® (meloxicam and rizatriptan) Clinical Program at the 67th Annual Scientific Meeting of the American Headache Society (AHS)

Axsome Therapeutics to Present Data Spanning the SYMBRAVO® (meloxicam and rizatriptan) Clinical Program at the 67th Annual Scientific Meeting of the American Headache Society (AHS)

Axsome Therapeutics Proudly Supports Migraine and Headache Awareness Month Alongside the Association of Migraine Disorders

Avidity Biosciences, Inc. (RNA) Initiated with a Strong Buy at Raymond James

JPMorgan Calls the Selloff Excessive, Trims Regeneron Pharmaceuticals, Inc. (REGN) Price Target

Jazz Pharmaceuticals Releases Unexpected Phase 4 Results Highlighting Xywav®

Axsome’s AXS-14 Gets Regulatory Setback with RTF, says Morgan Stanley

Analyst Kelly Shi from Jefferies Maintained a Buy Rating on Insmed Incorporated (INSM)

Axsome Therapeutics Showcases Innovation in Sleep Medicine with Multiple Presentations for AXS-12 and Solriamfetol at SLEEP 2025

Axsome Therapeutics Showcases Innovation in Sleep Medicine with Multiple Presentations for AXS-12 and Solriamfetol at SLEEP 2025

Axsome Therapeutics Announces Availability of SYMBRAVO® (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in Adults